MINI SUMMIT TOPICS LISTED BY CATEGORIES

NOTE: This is only a guide to help organize and manage topics. Please refer to the brochure for an accurate description of each Mini Summit to facilitate your selections as topics may fall into multiple categories.

AI AND DATA ANALYTICS	**MS 2: Enhancing Compliance and Overcoming Challenges under Corporate Integrity Agreements (CIA) through AI and Automation** **MS 12: Responsible AI at the Cusp of Scale** **MS 21: AI and Compliance Analytics: Real Case Studies for Managing HCP, HCO and Third-Party Risk** **MS 43: Detecting Bias in your AI Tools** **MS 46: Analytics and Monitoring: Understanding the Risks and Underlying Complexity of Today's Copay Program Landscape**
COMPLIANCE FRAMEWORK (SEVEN ELEMENTS)	**MS 3: Fostering a Speak Up Culture** **MS 4: Presenting to Senior Executives Effectively** **MS 9: Compliance Governance and Board of Directors** **MS 11: Targeted, Tailored, True-to-Life: How DOJ Guidance Should Shape Your Compliance Training** **MS 15: Balancing Compliance and Legal Roles and Responsibilities** **MS 16: Risk-Based Compliance Audits: Prioritizing What Matters Most** **MS 17: ESG Overload –A CCO's Guide to a Balanced Program Implementation** **MS 18: Compliance Training on the Digital Frontier** **MS 19: Substance over Form: Practical Approaches to Enterprise Risk Management (ERM)** **MS 26: Change Management for Compliance Program Transformation** **MS 29: Advancing Risk Management: A call to action for Integrated Risk Management (IRM) in Pharma** **MS 30: Attention Please! Elevating E&C Learning & Engagement in the Age of Distraction** **MS 35: Privacy Top-Ten: Strategies and Tactics to Address Operational Impacts of the Evolving Privacy Landscape** **MS 42: Best Practices in Investigations** **MS 51: Negotiating DOJ expectations and business challenges while creating a "Culture of Compliance"**
DRUG PRICING/ TRANSPARENCY	**MS 28: Government Programs and Compliance Office Oversight** **MS 31: Key Learnings from CMS Audits** **MS 41: Intersecting Reforms Affecting Drug Pricing** **MS 45: US Trends and Updates in HCP Spend Transparency and Drug Pricing Transparency** **MS 47: Lessons from Spend Transparency and Their Direct Application to Pricing Transparency**
HCP ENGAGEMENT	**MS 5: Interactions Between Sales and Medical Affairs** **MS 13: Hot Topics and Compliance Oversight in the Research and Development Area** **MS 22: Beyond Sales Representatives and MSLs: Considerations for Other FieldBased Roles** **MS 23: Fair Market Value: Navigating the Ongoing Changes in HCP Compensation Compliance** **MS 32: Exploring Risks and Enforcement Trends for Buy-and-Bill Drugs** **MS 39: HCP Expense Auditing and Monitoring** **MS 44: Evolving Risks in Medical Affairs**
PATIENT INTERACTIONS	**MS 10: Health Equity Initiatives —Compliance Considerations** **MS 20: Patient Support Programs and Patient Access Programs—A Look at the Evolution, Risks, and Enforcement Activity** **MS 25: Compliance Considerations for Rare Disease** **MS 33: Global Compliance Considerations for Designing Patient Support Programs**
REGULATORY ENFORCEMENT UPDATES	**MS 1: Federal Criminal and Civil Enforcement: Recent Highlights and Emerging Issues** **MS 6: Benchmarking and Brainstorming regarding Evolving Regulator Expectations relating to Off-Channel Communication** **MS 7: OIG New General Compliance Program Guidance** **MS 8: Update on Medical Device Regulatory and Enforcement Actions** **MS 14: Recent Developments in Enforcement Actions** **MS 24: Is Bigger Always Bad?Assessing Developing FTC Antitrust Enforcement Trends in Life Sciences** **MS 34: Qui Tam Declinations—Analysis and Trends When DOJ Declines to Intervene** **MS 36: Hot Topics in State Law Compliance** **MS 37: The Latest and Greatest in Enforcement and Guidelines for Social Media and Influencers** **MS 38: Compliance Considerations for Genetic Testing** **MS 48: State Law Updates— 2024 Recap and 2025** **MS 50: Market Access— Compliance Considerations When Resolving Disputes**
THIRD PARTY RISK MANAGEMENT	**MS 27: Service Fees: Hidden Compliance Risks and Downstream Market Access and Government Price Reporting Implications** **MS 40: The Role of Technology and Process Enhancements for Effective ABAC Third Party Vendor Diligence** **MS 49: Addressing Nuances in Third-Party Risk Management for Medical Devices**